Immune effector cell cytotoxicity (IECC)

Immune effector cell cytotoxicity refers to the biological process by which specialized immune cells, such as Natural Killer (NK) cells and Cytotoxic T Lymphocytes (CTLs), induce the death of target cells like tumor cells or virally infected cells. This process is not a single molecular target but a complex physiological mechanism involving the recognition of target antigens, the formation of an immunological synapse, and the subsequent release of cytotoxic granules containing perforin and granzymes, or the engagement of death receptors like FAS. In modern oncology, this mechanism is therapeutic context is leveraged by various drug classes, including immune checkpoint inhibitors (e.g., PD-1/PD-L1 blockers) which reinvigorate exhausted T cells, bispecific T-cell engagers (BiTEs) that bridge effector cells to tumor cells, and Chimeric Antigen Receptor (CAR) T-cell therapies. While it is a primary endpoint in many immunotherapy assays, 'Immune effector cell cytotoxicity' is classified as a functional phenotype or biological process rather than a discrete protein or receptor. Over-activation of this process can lead to serious adverse events, most notably cytokine release syndrome (CRS) and neurotoxicity.

Other names

Cell-mediated cytotoxicityAntibody-dependent cellular cytotoxicity (ADCC)T-cell mediated cytotoxicityNatural killer cell cytotoxicityEffector cell killing

Enhancement of cytotoxic activity via checkpoint inhibition, bispecific engagement, or CAR-T cell activation, leading to perforin and granzyme release.